introduced the bipartisan STOP GAMES Act ... The legislation aims to crack down on tactics used by big pharma to block cheaper, generic drugs from entering the market.
Lower prescription drug costs by cracking down on tactics big pharma uses to block cheaper generic drugs from entering the market.
Occurrences
My bipartisan STOP GAMES Act will crack down on tactics that Big Pharma uses to prevent cheaper, generic drugs from coming to market.
"I am so proud to be leading the bipartisan STOP GAMES Act," ... "This bill would crack down on Big Pharma while giving my neighbors the option to buy generic drugs, which can drive down costs by up to 95%."
The STOP GAMES Act is a bipartisan solution that helps get affordable generic drugs to market faster.
This announcement is part of Congressman Sorensen’s broader affordability plan to lower costs for working families and put money back in the pockets of his neighbors. From prescription drugs to everyday expenses, Sorensen is focused on delivering real results that help families keep more of what they earn. “Too many families are paying more than they should for prescription drugs because big pharmaceutical companies are gaming the system to block lower-cost competition,” said Congressman Sorensen. “The STOP GAMES Act is a bipartisan solution that helps get affordable generic drugs to market faster. This is an important step toward lowering costs for my neighbors and families across the country.”
Evidence
unverified · Source version 22067 · locator unknown
“I’m fighting to lower prescription drug costs by protecting and expanding Medicare's ability to negotiate drug prices, and I have a bill to stop Big Pharma’s price gouging that is preventing cheaper generics from getting onto pharmacy shelves.”
unverified · Source version 22068 · locator unknown
“My bill, the STOP GAMES Act, addresses their tactic. STOP GAMES cracks down on citizen petitions filed not to improve safety, but to delay competition. Often filed at the last minute, these duplicative and unsupported petitions stall generic approvals for years, all the while keeping prices high for patients... STOP GAMES gives the FDA clear authority to quickly reject petitions whose...”
unverified · Source version 22069 · locator unknown
Sponsor: Rep. Sorensen, Eric [D-IL-17] (Introduced 04/28/2023). Latest Action: House - 05/05/2023 Referred to the Subcommittee on Health. Tracker: Tip | This bill has the status Introduced.
unverified · Source version 22070 · locator unknown
“These ‘pay-for-delay’ patent settlements effectively block all other generic drug competition for a growing number of branded drugs.” The FTC says it supports legislation to end such anticompetitive settlements.
unverified · Source version 22071 · locator unknown
“Section 505(q) was added to the FD&C Act in 2007 to limit the potential for certain citizen petitions to be employed as a means to delay approval of generic and certain other applications.”
unverified · Source version 54565 · locator unknown
"submitted with the primary purpose of delaying the approval of an application ... the Secretary may deny the petition"
unverified · Source version 54567 · locator unknown
"H.R. 9393 ... was forwarded to the Full House, as amended, by a roll call vote of 45 yeas - 0 nays."
unverified · Source version 67410 · locator unknown
"Mr. Sorensen (for himself and Mrs. Bice) introduced the following bill; which was referred to the Committee on Energy and Commerce"
unverified · Source version 67412 · locator unknown
"If the Secretary determines that a petition has been submitted with the primary purpose of delaying the approval of an application... the Secretary shall refer the matter to the Federal Trade Commission."
Assessments
The promise was to lower prescription drug costs by cracking down on brand-drug company tactics that delay generic competition. The record shows Sorensen did make a serious effort: he publicly promoted this goal and introduced the STOP GAMES Act of 2023 to target abusive citizen petitions used to delay generics. However, the official legislative status provided shows the bill was only introduced and referred to subcommittee, with no evidence of enactment, broader passage, or another completed federal policy change attributable to Sorensen that fulfilled the promise. Background evidence from FTC and FDA confirms the problem is real, but not that Sorensen delivered the promised outcome. Under the rule for serious but unsuccessful attempts, this is best scored as never, with effort credit.